Upstream Bio, Inc. (UPB) - Net Assets
Based on the latest financial reports, Upstream Bio, Inc. (UPB) has net assets worth $378.58 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($391.19 Million) and total liabilities ($12.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Upstream Bio, Inc. (UPB) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $378.58 Million |
| % of Total Assets | 96.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Upstream Bio, Inc. - Net Assets Trend (2022–2024)
This chart illustrates how Upstream Bio, Inc.'s net assets have evolved over time, based on quarterly financial data. See how many days can Upstream Bio, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Upstream Bio, Inc. (2022–2024)
The table below shows the annual net assets of Upstream Bio, Inc. from 2022 to 2024. For live valuation and market cap data, see UPB company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $469.85 Million | +481.60% |
| 2023-12-31 | $-123.13 Million | -15.99% |
| 2022-12-31 | $-106.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Upstream Bio, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8334300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $53.00K | 0.01% |
| Other Comprehensive Income | $-25.00K | -0.01% |
| Other Components | $660.60 Million | 140.60% |
| Total Equity | $469.85 Million | 100.00% |
Upstream Bio, Inc. Competitors by Market Cap
The table below lists competitors of Upstream Bio, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hubei Mailyard Share Co Ltd
SHG:600107
|
$332.41 Million |
|
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
SHG:600613
|
$332.46 Million |
|
Biofarm Bucure
RO:BIO
|
$332.60 Million |
|
LTC Co.Ltd
KQ:170920
|
$332.72 Million |
|
Indo Thai Securities Limited
NSE:INDOTHAI
|
$332.31 Million |
|
Tibet Galaxy Science & Technology Development Co Ltd
SHE:000752
|
$332.31 Million |
|
Maui Land & Pineapple Company Inc
NYSE:MLP
|
$332.27 Million |
|
Esso (Thailand) Public Company Limited
BK:BSRC
|
$332.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Upstream Bio, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -123,126,000 to 469,852,000, a change of 592,978,000.
- Net loss of 62,806,000 reduced equity.
- New share issuances of 422,647,000 increased equity.
- Other comprehensive income decreased equity by 46,000.
- Other factors increased equity by 233,183,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-62.81 Million | -13.37% |
| Share Issuances | $422.65 Million | +89.95% |
| Other Comprehensive Income | $-46.00K | -0.01% |
| Other Changes | $233.18 Million | +49.63% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Upstream Bio, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.67x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-2.92 | $6.15 | x |
| 2023-12-31 | $-3.39 | $6.15 | x |
| 2024-12-31 | $9.15 | $6.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Upstream Bio, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2650.04%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-13.37%) is below the historical average (-4.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -1969.31% | 0.07x | 0.00x | $-13.25 Million |
| 2023 | 0.00% | -862.90% | 0.02x | 0.00x | $-8.22 Million |
| 2024 | -13.37% | -2650.04% | 0.00x | 1.03x | $-109.79 Million |
Industry Comparison
This section compares Upstream Bio, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Upstream Bio, Inc. (UPB) | $378.58 Million | 0.00% | 0.03x | $332.34 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporat… Read more